Transformujący czynnik wzrostu β1 (TGFβ1) i naczyniowo-śródbłonkowy czynnik wzrostu (VEGF) we krwi ludzi zdrowych i chorych z orbitopatią Gravesa — nowy mechanizm działania glikokortykosteroidów?

Kajdaniuk, Dariusz; Marek, Bogdan; Niedziołka-Zielonka, Danuta; Fołtyn, Wanda; Nowak, Mariusz; Siemińśka, Lucyna; Borgiel−Marek, Halina; Głogowska-Szeląg, Joanna; Ostrowska, Zofia; Drożdż, Lucjan; Kos–Kudła, Beata

doi:10.5603/ep.2014.0048

Cited by 10 publications

(6 citation statements)

References 59 publications

(84 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings are consistent with several studies demonstrating an increase in serum concentration of proangiogenic factors in patients with Graves’ disease [ 5 , 36 , 37 ]. However, to the best of our knowledge, our study is the first to evaluate HGF concentration in Graves’ disease patients with clinically active GO.…”

Section: Discussionsupporting

confidence: 93%

“…We had found that 1 month after the end of additional oral MP treatment, serum concentration of PDGF-AA decreased compared to the values after i.v.MP treatment and no significant difference was observed in the value between Group A2 and the control. However, serum concentration of VEGF was still significantly higher as compared to the control [ 5 , 30 ].…”

Section: Discussionmentioning

confidence: 99%

“…Graves’ orbitopathy is an autoimmune disease in which CD4+ and CD8+ T cells, B cells, plasma cells, and macrophages infiltrate the orbital and periorbital soft tissues, which results in tissue remodelling and oedema. Enlargement of the orbital tissue volume occurs through the accumulation of the extracellular matrix, scar-forming myofibroblasts, and/or fat proliferation [ 5 , 6 ]. Orbital T cells, fibroblasts, adipocytes and perhaps other residential cells may release numerous cytokines, growth factors, and inflammatory mediators, many of which act as potent stimulators of glycosaminoglycan accumulation and oedema formation.…”

Section: Introductionmentioning

confidence: 99%

“…This is an area where new treatment approaches are greatly needed. In previous papers, authors found an important role of different proangiogenic factors such as VEGF, PDGF, or TGFβ1 in the pathogenesis of GO and its correlation with clinical activity of the disease [ 5 , 28 – 30 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Serum concentrations of HGF and IL-8 in patients with active Graves’ orbitopathy before and after methylprednisolone therapy

Nowak

Siemińśka

Karpe

et al. 2015

J Endocrinol Invest

View full text Add to dashboard Cite

IntroductionGraves’ disease is the most common cause of hyperthyroidism, and orbitopathy is the most frequent extrathyroidal manifestation of Graves’ disease. The aims of this study were as follows: (1) to evaluate the serum concentration of HGF and IL-8 in the blood of newly diagnosed Graves’ disease patients with the first episode of active GO and healthy controls; (2) to estimate the influence of the thyroid function (euthyreosis vs. hyperthyreosis) on HGF and IL-8 blood levels in patients with active GO; (3) to evaluate the influence of intravenous (i.v.) methylprednisolone (MP) pulse therapy and additional oral MP treatment on HGF and IL-8 blood levels in patients with active GO.Patients and methodsThirty-nine Graves’ disease patients with the first episode of clinically active GO (Group A) were enrolled in the study. To estimate the influence of the thyroid function on serum concentrations of the studied proangiogenic factors, Group A was divided into Group A I (n = 18) in euthyroid and Group A II (n = 21) in hyperthyroid stage of Graves’ disease in moderate-to-severe stage of GO. The control group consisted of 20 healthy volunteers age- and sex-matched to the GO group. Concentrations of the studied proangiogenic factors in serum samples were measured by an enzyme-linked immunosorbent assay before (Group A) and after (Group A1) intensive pulse i.v.MP treatment and 1 month after the end of additional oral MP treatment (Group A2).ResultsWe found a significant increase in serum concentrations of studied factors in the GO group before immunosuppressive therapy when compared with the control group and decrease after i.v.MP treatment. One month after the end of additional oral MP treatment (Group A2), serum concentrations of HGF and IL-8 still decreased and no significant difference was observed in HGF and IL-8 concentrations when compared with the control group. We did not find the difference in serum concentration of the studied proangiogenic factors between patients in euthyroid and hyperthyroid stage of Graves’ disease before MP therapy.ConclusionsSerum HGF and IL-8 concentrations are elevated in Graves’ disease patients with active Graves’ orbitopathy as compared to the healthy control group. Successful management of active Graves’ orbitopathy with glucocorticoids is associated with a decrease in HGF and IL-8 serum concentrations.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum concentrations of HGF and IL-8 in patients with active Graves’ orbitopathy before and after methylprednisolone therapy

Nowak

Siemińśka

Karpe

et al. 2015

J Endocrinol Invest

View full text Add to dashboard Cite

show abstract

“…VEGF has a central role in the pathogenesis of diverse cancers and blinding eye diseases ( Apte et al, 2019 ), and serum VEGF levels are significantly increased in patients with active TAO, reflecting the degree of ocular inflammatory activity and long-standing autoimmune processes in orbital and thyroid tissues. Increased VEGF levels also promote thyroid gland angiogenesis ( Kajdaniuk et al, 2014 ; Ye et al, 2014 ). However, the relationship between the above 3 tRFs and mTOR/VEGF signaling needs further exploration.…”

Section: Discussionmentioning

confidence: 99%

Identification of tRNA-Related Fragments and Their Potential Regulatory Effects in Thyroid-Associated Ophthalmopathy

et al. 2022

View full text Add to dashboard Cite

Recently, the potential role of tRNA-related fragments (tRFs) in ophthalmic diseases has been extensively researched. However, systematic studies on the potential regulatory effects of tRFs in thyroid-associated ophthalmopathy (TAO) are lacking. We used high-throughput sequencing techniques to measure expression levels of mRNAs and tRFs in patients with TAO, and the results were verified by real-time quantitative reverse transcription polymerase chain reaction (q-PCR). Next, the potential biological regulatory effect of differentially expressed tRFs was analyzed, and potential downstream target RNAs of differentially expressed tRFs were predicted to explore the potential role of tRFs as therapeutic targets and biomarkers of TAO. A total of 50 tRFs and 361 mRNAs were dysregulated in the TAO group, and tRF5-GluCTC, PMAIP1, HSD17B2 and ATF3 were verified to be significantly differentially expressed in TAO. Our research reveals that several associated pathways likely play a role in the pathogenesis of TAO. By targeting ATF3, HSD17B2 and PMAIP1, tRF5-GluCTC may play a potential role in regulating the orbital fibroblast adipogenic response and fibrotic hyperplasia in patients with TAO.

show abstract

Early response to intravenous methylprednisolone therapy for restrictive myopathy in patients with thyroid eye disease

Jang

Park

et al. 2023

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Transformujący czynnik wzrostu β1 (TGFβ1) i naczyniowo-śródbłonkowy czynnik wzrostu (VEGF) we krwi ludzi zdrowych i chorych z orbitopatią Gravesa — nowy mechanizm działania glikokortykosteroidów?

Cited by 10 publications

References 59 publications

Serum concentrations of HGF and IL-8 in patients with active Graves’ orbitopathy before and after methylprednisolone therapy

Serum concentrations of HGF and IL-8 in patients with active Graves’ orbitopathy before and after methylprednisolone therapy

Identification of tRNA-Related Fragments and Their Potential Regulatory Effects in Thyroid-Associated Ophthalmopathy

Early response to intravenous methylprednisolone therapy for restrictive myopathy in patients with thyroid eye disease

Contact Info

Product

Resources

About